Publications
Denis Roy, MD, FACC, Brian H. Rowe, MD, MSC, Ian G. Stiell, MD, MSC, Benoit Coutu, MD, John H. Ip, MD, Denis Phaneuf, MD, Jacques Lee, MD, MSC, Humberto Vidaillet, MD, FACC, Garth Dickinson, MD, Sheila Grant, MBA, Alan M. Ezrin, PHD, Gregory N. Beatch, PHD, A Randomized, Controlled Trial of RSD1235, a Novel Anti-Arrhythmic Agent, in the Treatment of Recent Onset Atrial Fibrillation for the CRAFT Investigators. Journal of the American College of Cardiology 2004 44(12) 2355-2361.
GN Beatch, M Helmes, Y Blaauw, and MA Allessie. Acute Reversal of Electrical Remodeling and Cardioversion of Persistent AF by a Novel Atria-Selective Antiarrhythmic Drug, RSD1235, in the Goat. Circulation 110(17):III-163, 2004 abstract #778.
PMR Orth, L Lynn, Y Yang, JC Hesketh, CM Mak, GN Beatch, AM Ezrin D Fedida. The Novel AF Conversion Agent RSD1235 Terminates EADs and Prevents Torsades de Pointes in a Rabbit Model. Circulation 110(17):III-742, 2004 abstract #3433.
P Dorian, I Mangat, V Korley, GN Beatch, S Cvitkovic, A Pinter. Electrophysiological Properties of an Atrial Selective Antiarrhythmic Agent, RSD1235, in Humans. Circulation 110(17):III-461, 2004 abstract #2172.
P Dorian, I Mangat, V Korley, GN Beatch, S Cvitkovic, A Pinter. Electrophysiological Properties of an Atrial Selective Antiarrhythmic Agent, RSD1235, in Humans. Can J Cardiol 20:198D, 2004 abstract 594.
Roy D, Beatch GN, Steill, I, Ip JH, Coutu B, Phaneuf D, Rowe B, Ezrin AM. RSD1235 rapidly and effectively terminates atrial fibrillation. Eur. Heart J. 24:720, 2003, abstract #3699.
Beatch GN, Lin S-P, Hesketh JC, Johnson BD, Ezrin AM, Fedida D. Electrophysiological mechanism of RSD1235, a New Atrial Fibrillation Converting Drug. Circulation 108(17):IV-85, 2003 abstract #400.
GN Beatch, SM Grant, L Clohs, AM Ezrin. RSD1235, A Novel Atrial-Selective Antiarrhythmic Drug, Shows Rapid and Extensive Oral Absorption in Man. Abstract presented at the 12th International Congress on Cardiovascular Pharmacotherapy, May 7-10, 2003. Barcelona, Spain
John Christian Hesketh, Gregory N Beatch, Alan M Ezrin, Barry D Johnson, David Fedida Safety of RSD1235 in a rabbit Purkinje fiber model Meeting abstract 22.12 for presentation at XIV World Congress of Pharmacology, July 7-12, 2002, San Francisco, CA; Pharmacologist 2002, 44(2), Supplement 1, A15.
Ezrin AM, Grant SM, Bell G, Jung G, Clohs L, Johnson B, Kisicki JC, Beatch GN. A Dose-Ranging Study of RSD1235, a Novel Antiarrhythmic Agent, in Healthy Volunteers. Meeting abstract 22.10 for XIV World Congress of Pharmacology, July 7-12, 2002, San Francisco, CA; Pharmacologist 2002, 44(2), Supplement 1, A15.
Beatch GN, Shinagawa K, Johnson B, Jung G, Plouvier B, Zolotoy A, Ezrin AM, Walker MJA, and Nattel S. RSD1235 Selectively Prolongs Atrial Refractoriness and Terminates AF in Dogs with Electrically Remodeled Atria. Meeting abstract 702 for the North American Society of Pacing and Electrophysiology 23rd Annual Scientific Sessions, May 8-11, 2002, San Diego, CA; Pacing and Clinical Electrophysiology 2002, 25(4), Part II, p 698.
Beatch GN, Shinagawa K, Johnson B, Jung G, Plouvier B, Zolotoy A, Ezrin AM, Walker MJA, and Nattel S. RSD1235 Selectively Prolongs Atrial Refractoriness and Terminates AF in Dogs with Electrically Remodeled Atria. Meeting abstract 22.11 for XIV World Congress of Pharmacology, July 7-12, 2002, San Francisco, CA; Pharmacologist 2002, 44(2), Supplement 1, A15.